New cancer-targeting therapy using platelet vector containing viral particles with anti-tumor activities

2015 Fiscal Year Final Research Report

• Project/Area Number: 25290056
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Partial Multi-year Fund
• Section: 一般
• Research Field: Tumor therapeutics
• Research Institution: Osaka University
• Principal Investigator: Kaneda Yasufumi 大阪大学, 医学(系)研究科(研究院), 教授 (10177537)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: 腫瘍標的ベクター / HVJ envelope / 血小板 / 抗腫瘍免疫

Outline of Final Research Achievements

Inactivated Sendai virus (hemagglutinating virus of Japan; HVJ) envelope (HVJ-E) with anti-tumor activities were incorporated into mouse platelets.The hemagglutination activity which disturbs systemic administration of HVJ-E was dramatically attenuated by incorporation into platelets. Then, platelets incorporating HVJ-E (PH complex) were injected into the tail veins of B16F10 melanoma-bearing mice. The PH complex dominantly accumulated in tumor tissues and significantly suppressed melanoma growth in mice. Lung metastasis was also suppressed by susyemic administration of PH complex. Chemokine, IP-10, was also incorporated into platelet vector. The IP-10/platelet also suppressed melanoma growth in mic by systemic administration. Thus, the platelet vector incorporating anti-tumor reagents will provide a new approach for cancer-targeting therapy using oncolytic viruses.

Free Research Field

腫瘍治療学